Vaccine and biologic purchasing for primary care practices

Vaccine and biologic purchasing for primary care practices

Most supply categories are a rounding error. Vaccines and buy and bill biologics are not. These are the categories where the practice lays out real money in advance, holds inventory that can spoil or expire, and gets reimbursed at a rate it does not set. Acquisition cost is the only variable in that equation the practice controls.

Which is why the way a practice buys these products decides whether the category makes money or quietly loses it.

Two supply chains, not one

A practice that gives childhood vaccines is running two separate purchasing operations at once, and confusing them is a common and expensive mistake.

The public one. The Vaccines for Children program provides vaccine at no cost for eligible children through enrolled providers. Congress created it in the Omnibus Budget Reconciliation Act of 1993, it became operational on October 1, 1994, and it operates as Section 1928 of the Social Security Act. It is an entitlement for eligible children aged 18 and younger (CDC).

The mechanics matter. Funding is approved by the Office of Management and Budget and allocated through CMS to the CDC. The CDC then buys the vaccines at a discount and distributes them to VFC providers at the direction of the 63 state, local, and territorial immunization programs that administer the program. Those doses arrive at no charge to enrolled providers, and enrolled private providers can receive publicly purchased vaccine (CDC).

The private one. For everyone not covered by VFC, and for every adult vaccine, the practice buys the product itself. Private providers cannot purchase through CDC contracts. CDC publishes both contract prices and private sector prices in its vaccine price lists, but the private sector prices are figures that manufacturers report to CDC annually for general information, and CDC directs questions about them to the manufacturers (CDC).

So the published private sector price is a reference point, not a price you are offered. What you actually pay depends on your contracts.

That second supply chain is where group purchasing operates, and it is the one most practices have never negotiated.

Why the vaccine line is unforgiving

Vaccines have a set of characteristics that combine badly for a small buyer.

You buy ahead of demand, sometimes many months ahead for seasonal products. You carry the inventory and the cold chain. Product expires. Reimbursement is set by payers rather than by you. And the difference between a good acquisition price and a poor one is frequently wider than your entire margin on the administration.

None of that is fixable by working harder. It is fixable by buying better.

The same logic applies to buy and bill biologics

Any product a practice purchases and then bills for after administering it sits in the same structure. The practice fronts the cost, holds the inventory, absorbs the waste, and collects a reimbursement it did not negotiate.

When acquisition cost moves toward reimbursement, the category stops working. Practices usually discover this after the fact, because the loss does not show up as a loss. It shows up as a service line that never seems to contribute much, and the instinct is to blame utilization or coding rather than the purchase price.

Two questions are worth asking about every buy and bill product you stock. What did we pay for it, compared to what a large buyer pays. And do we know that, or are we assuming it.

Most practices cannot answer the first with confidence, which is itself the answer.

What group purchasing changes here

A group purchasing organization negotiates on behalf of the pooled volume of many buyers, so a practice buys at a price the collective earned rather than the price its own volume commands. The ordering process does not change. The invoice does.

The savings come from two directions. Lower prices through joint negotiation, and lower transaction costs because the contracting work is done once centrally instead of repeated by every practice (HSCA).

The commonly cited range for providers buying through GPOs is 10 to 18 percent against what they would have negotiated alone (HSCA).

Two features matter specifically for vaccines and biologics.

Nothing about your ordering changes. You keep your distributor relationships and your ordering process. Pricing is what moves.

Nothing is mandatory. GPO contracts are voluntary and providers can buy off contract at any time (HSCA). If your existing arrangement on a product is better, keep it. Group purchasing gives you a floor to compare against, which is more than most practices have today.

A short diagnostic

If you want to know whether this category is worth your attention, work through these.

Do you know your acquisition cost per dose on your top five vaccines, without looking it up?

Do you know how much product you wrote off to expiry last year?

Are you enrolled in VFC, and if so, are your public and private inventories tracked separately?

For every buy and bill product you stock, do you know your margin after acquisition cost and waste?

Has anyone negotiated your private purchase pricing in the last two years, or has it rolled forward on autopilot?

A practice that cannot answer most of these is not being careless. It is being normal. Nobody in a typical practice has procurement as their job, and that is precisely the gap group purchasing was built to close.

One Harbor Alliance contracts on behalf of ACOs, MSOs, CINs, FQHCs, and independent physician practices. Participation is voluntary, joining costs nothing, and you keep buying from whoever you buy from now. If you want to see what your own vaccine and biologic lines look like against contract pricing, start with a question.